MedTrace Logo

Sugammadex and Quantitative Monitoring in "Fast-Track Anesthesia" During Liver Transplantation

NCT05216991 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2025-10-24

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to estimate the frequency of postoperative lasting muscle weakness in patients receiving Sugammadex after undergoing liver transplant surgery by using electromyographic device (EMG), such as TetraGraph.

Conditions

  • Liver Transplant Surgery

Interventions

OTHER

TetraGraph on dominant hand

Using standard of care TetraGraph device on dominant hand

OTHER

TetraGraph on non-dominant hand

Using standard of care TetraGraph device on non-dominant hand

Sponsors & Collaborators

Principal Investigators

  • J. Ross Renew, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-20
Primary Completion
2025-01-21
Completion
2025-01-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05216991 on ClinicalTrials.gov